Funding for this research was provided by:
Hellenic Institute for the Study of Sepsis
Received: 14 June 2020
Accepted: 9 November 2020
First Online: 19 November 2020
Ethics approval and consent to participate
: The study was registered (CIV-19-06-028824). It was approved by the National Ethics Committee of Greece (approval MD 3/19) and by the National Organization for Medicine of Greece (approval MD 3/19). Written informed consent was provided by the patients or by first-degree relatives in case of patients not able to consent.
: Not applicable.
: M. Rodencal and R. Newberry are employees of Sanmina Corporation.K. Stamatelopoulos reports research funding and honoraria from Amgen.EJ Giamarellos-Bourboulis has received honoraria (paid to the University of Athens) from Abbott CH, Biotest Germany, Brahms GmbH, InflaRx GmbH, MSD Greece. Pfizer Greece, and XBiotech Inc. He has received independent educational grants from AbbVie, Abbott, Astellas Pharma, AxisShield, bioMérieux Inc., InflaRx GmbH, Novartis Inc. and XBiotech Inc. He has received funding from the FrameWork 7 program HemoSpec, from the Horizon2020 Marie-Curie project European Sepsis Academy (granted to the National and Kapodistrian University of Athens) and from the Horizon2020 HemoSpec (granted to the Hellenic Institute for the Study of Sepsis).All other authors have disclosed that they do not have any conflicts of interest relevant to this submission.Sanmina Corporation took part in the analysis and interpretation of data, and the writing of the manuscript.